Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
HUTCHMED (China) Limited
和黃醫藥（中國）有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 13)
MAJOR TRANSACTION
IN RELATION TO
THE DISPOSAL OF 45% EQUITY INTEREST IN
SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED
TIMING OF DISPATCH OF CIRCULAR
Reference is made to the announcement of HUTCHMED (China) Limited (the “Company”) dated January 1, 2025 (the “Announcement”) in relation to the proposed disposal of 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.
In the Announcement, it was mentioned that the Circular containing, among other things, (i) further details on the terms of the Proposed Disposal; and (ii) other information as required under the Listing Rules together with a notice convening the EGM, was expected to be dispatched to the Shareholders on or before January 28, 2025.
GP Health Service Capital has notified the Seller that additional time is required for it to designate the GP Purchaser Fund and the Designated Purchaser, taking into account the Chinese New Year holidays. In view of this, the Company currently expects that the Circular will be dispatched to the Shareholders on or before February 28, 2025.
The Proposed Disposal is subject to all of the conditions under the Agreements being satisfied (or, if applicable, waived) and therefore may or may not become unconditional. If any of the conditions under the Agreements is not satisfied (or, if applicable, waived), the Proposed Disposal will not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the shares and other securities of the Company.
By Order of the Board
Edith Shih
Non-executive Director and Company Secretary
Hong Kong, January 28, 2025
As at the date of this announcement, the Directors of the Company are:
Chief Scientific Officer) | |
Chairman and Non-executive Director: Dr Dan ELDAR Executive Directors: Dr Weiguo SU (Chief Executive Officer and
Chief Scientific Officer) Mr CHENG Chig Fung, Johnny (Chief Financial Officer) | Non-executive Directors: Ms Edith SHIH Ms Ling YANG Independent Non-executive Directors: Mr Paul Rutherford CARTER (Senior Independent Director) Dr Renu BHATIA Dr Chaohong HU Mr Graeme Allan JACK Professor MOK Shu Kam, Tony |
